Company Analysis Unity Biotechnology, Inc.
1. Summary
Advantages
- Price (1.74 $) is less than fair price (1.77 $)
- The stock's return over the last year (16%) is higher than the sector average (-22.93%).
Disadvantages
- Dividends (0%) are below the sector average (0.5448%).
- Current debt level 41.09% has increased over 5 years from 0.0298%.
- The company's current efficiency (ROE=-140.36%) is lower than the sector average (ROE=9.69%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Unity Biotechnology, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -1.1% | -20% | 0.2% |
| 90 days | 56.8% | -23.9% | -10.2% |
| 1 year | 16% | -22.9% | 9.1% |
UBX vs Sector: Unity Biotechnology, Inc. has outperformed the "Healthcare" sector by 38.93% over the past year.
UBX vs Market: Unity Biotechnology, Inc. has outperformed the market by 6.91% over the past year.
Stable price: UBX is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: UBX with weekly volatility of 0.3077% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (1.74 $) is lower than the fair price (1.77 $).
Price not significantly lower than the fair price: The current price (1.74 $) is slightly lower than the fair price by 1.7%.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (57.21).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (48.7).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.8324) is lower than that of the sector as a whole (4.65).
P/BV vs Market: The company's P/BV (0.8324) is lower than that of the market as a whole (3.42).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (101.78) is higher than that of the sector as a whole (33.44).
P/S vs Market: The company's P/S indicator (101.78) is higher than that of the market as a whole (10.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-0.7907) is higher than that of the sector as a whole (-17.68).
EV/Ebitda vs Market: The company's EV/Ebitda (-0.7907) is lower than that of the market as a whole (25.23).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -11.43% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-11.43%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (156.84%).
5.4. ROE
ROE vs Sector: The company's ROE (-140.36%) is lower than that of the sector as a whole (9.69%).
ROE vs Market: The company's ROE (-140.36%) is lower than that of the market as a whole (8.97%).
5.5. ROA
ROA vs Sector: The company's ROA (-60.68%) is lower than that of the sector as a whole (0.2896%).
ROA vs Market: The company's ROA (-60.68%) is lower than that of the market as a whole (6.31%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-50.19%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-50.19%) is lower than that of the market as a whole (10.96%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5448%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
